Condition: Generalized Myasthenia Gravis · Sponsor: Novartis Pharmaceuticals
This is a phase I/II study to assess safety, efficacy, and cellular kinetics of YTB323 in participants with treatment-resistant generalized myasthenia gravis. YTB323 is a Biological CAR-T cell therapy.
This description comes directly from the study's public registry record.
Novartis Pharmaceuticals · 1-888-669-6682 · novartis.email@novartis.com
Novartis Pharmaceuticals · +41613241111
Always discuss trial participation with your own doctor first.
| Univ Cali Irvine ALS Neuromuscular | Orange, California, United States | Recruiting |
| Wake Forest Univ School of Medicine | Winston-Salem, North Carolina, United States | Recruiting |
| Thomas Jefferson University | Philadelphia, Pennsylvania, United States | Recruiting |
| Houston Methodist Hospital | Houston, Texas, United States | Recruiting |
| Novartis Investigative Site | Bordeaux, France | Recruiting |
| Novartis Investigative Site | Brest, France | Recruiting |
| Novartis Investigative Site | Lille, France | Recruiting |
| Novartis Investigative Site | Chiba, Chiba, Japan | Recruiting |
| Novartis Investigative Site | Kyoto, Japan | Recruiting |
| Novartis Investigative Site | Sheffield, South Yorkshire, United Kingdom | Recruiting |
| Novartis Investigative Site | London, United Kingdom | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06704269